FDA Approves Revolution Medicines' Rasonque for Metastatic Pancreatic Cancer
RVMD has more than doubled off its 52-week low of $35.62.
Summary
The FDA approved daraxonrasib (Rasonque) for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy. The approval is based on a 500-patient study showing overall survival of 13.2 months versus 6.7 months on standard chemotherapy. This is the first FDA approval for Revolution Medicines and validates its RAS-targeting platform. The drug is a once-daily pill that blocks multiple RAS mutations, a key driver in pancreatic cancer. Pricing and launch timing have not been disclosed. The stock is trading near its 52-week high, reflecting high expectations; this approval removes a major regulatory risk.
Updates
· SEC 8-K — RASONQUE's wholesale acquisition cost is $39,800 for a 30-day supply. The drug is now available for physicians to prescribe.
At the time of this announcement, RVMD was trading at $213.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.3B. The 52-week trading range was $35.62 to $220.34. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.